AMA Morning Rounds: Lithium may not help patients with ALS

The AP (4/6, Cheng) reports, "Lithium doesn't help patients with ALS, or Lou Gehrig's disease, contrary to previous study results, new research says." For the "first trial to scientifically assess whether lithium works for Lou Gehrig's disease, doctors found it had no effect -- and stopped the study early because it seemed futile." Eighty-four "patients with Lou Gehrig's disease" were enrolled in the study, and after "nearly six months, researchers didn't see any difference: 22 of the 40 patients in the lithium group had gotten worse versus 20 of 44 patients in the placebo group." The Los Angeles Times (4/5, Maugh) "Booster Shots" blog and MedPage Today (4/5, Gever) also covered the story.

AMA Morning Rounds: FDA grants orphan drug status to potential ALS treatment.

The AP (3/10) reported, "Cytokinetics Inc. said Wednesday regulators have granted 'orphan drug' status to its potential" amyotrophic lateral sclerosis, or "Lou Gehrig's disease treatment." The company also "said it plans to start a mid-stage clinical trial in the first half of this year to test the drug's effectiveness." Reuters (3/10, Sengupta) noted that the drug is called CK-2017357.

AMA Morning Rounds: Early data for ALS drug candidate shows improved muscle function

The AP (12/10) reports, "Sangamo Biosciences Inc. said Wednesday that early data from a clinical trial shows its Lou Gehrig's disease drug candidate," SB-509, "improved patients' muscle function." Patients injected with the drug "were about twice as likely to have improved muscular function," according to Sangamo. Specifically, "32 percent of patients who received SB-509 had improved muscle function, compared to 17 percent of patients who took standard treatments." The company "is also testing SB-509 as a treatment for diabetic neuropathy."

AMA Morning Rounds: FDA lifts clinical hold on CytRx Lou Gehrig's treatment

The AP (12/2) reported that the FDA "lifted a nearly two-year suspension on development of" CytRx Corp.'s "arimoclomol as a treatment for Lou Gehrig's disease." The agency "halted arimoclomol studies" in January 2008, "citing the need for additional analysis from previously completed animal studies with arimoclomol."

Reuters (12/2) reported that the FDA accepted CytRx's revised trial protocol to review the safety and efficacy of the experimental drug at four times the dose previously studied. The FDA has granted the drug a fast-track review and orphan drug status to treat Lou Gehrig's disease.

AANEM Endorses AAN Guidelines on ALS

The AAN announced the publication of two new evidence-based guidelines on caring for patients with ALS today. The AANEM endorsed both documents in advance of their publication in the journal Neurology. 

The first guideline addresses drug, nutritional, and respiratory therapies. The second guideline examines the benefits of multidisciplinary care, symptom management, and cognitive/behavioral impairment.  Additional resources, including two clinician summaries, two patient summaries, a slide presentation, a clinical example, and a podcast, were also created for the guidelines